Phosphagenics' oxymorphone patch storms phase I
24 October, 2013 by Dylan Bushell-EmblingShares in Phosphagenics (ASX:POH) climbed 42% after the company reported strong plasma concentrations from the first in-human trial of opioid pain patch TPM/oxymorphone.
Challenges in the biotech business
23 October, 2013 by Susan WilliamsonEstablishing a small biotech company and getting products to market are just some of the challenges facing companies in the Australian biotech sector.
Immuron granted US Travelan patent
23 October, 2013 by Dylan Bushell-EmblingImmuron (ASX:IMC) has secured a US patent covering products developed with its colostrum platform technology, as it progresses with talks to bring Travelan to the US.
pSivida shares slide after third FDA knockback
22 October, 2013 by Dylan Bushell-EmblingThe US FDA has for the third time rejected pSivida (ASX:PVA) licensee Alimera Sciences' NDA for diabetic macular edema treatment Iluvien.
Last chance to register for the biotech industry event of the year: AusBiotech 2013
22 October, 2013Brisbane will welcome more than 1000 of the brightest brains in biotechnology and innovation next week for the official launch of the AusBiotech 2013 national conference; a premier event on the Australian and Asia-Pacific calendar.
Coridon hits dosing milestone in herpes trial
17 October, 2013 by Dylan Bushell-EmblingThe 20 subjects enrolled in a trial of the HSV-2 vaccine under development at Allied Healthcare's (ASX:AHZ) Coridon have all received two out of three planned doses.
Technical guidelines for therapeutic services open for comment
17 October, 2013The Department of Health and Ageing has released draft technical guidelines for therapeutic services, open for consultation until 23 November 2013.
iSonea teams with uHealth for AirSonea push
16 October, 2013 by Dylan Bushell-EmblingSydney-based uHealth will work with iSonea (ASX:ISN) to pursue more sales opportunities for the latter's asthma symptom monitoring device, AirSonea.
Bioeconomy in transition
16 October, 2013 by Susan WilliamsonThis year’s AusBiotech conference will focus on the transformation of the Australian biotech industry, following its evolution and the application of its bioactivity across areas such as agriculture, food technology and health. In this preview we provide a bumper sample of what’s in store for Brisbane at the end of October.
Ellex eye treatment shows promise in early AMD
15 October, 2013 by Dylan Bushell-EmblingResults from a pilot trial of Ellex Medical Lasers' (ASX:ELX) Retinal Rejuvenation Therapy (2RT) suggest the treatment could act as an early intervention therapy for AMD.
QRxPharma expands MoxDuo deal with Aspen
15 October, 2013 by Dylan Bushell-EmblingA month after licensing MoxDuo IR for ANZ and Oceania to Aspen for $1.25m, QRxPharma (ASX:QRX) has expanded the deal to also cover South Africa.
Stem sells for Regeneus
15 October, 2013 by Dylan Bushell-EmblingRegeneus, a Sydney-based company with a strong pipeline of cell-based treatments derived from adipose tissue, raised $10.5m last month in a fully subscribed IPO.
Austrade to lead 'Australia-India Innovation in Life Sciences Roadshow'
15 October, 2013Austrade, in partnership with Australian federal and state government agencies, is organising the first Australian 'Innovation Week' in India and invites interested Australian companies to participate. While the entire program will run over three weeks, the life sciences component will run for one week, commencing 25 November 2013.
Mesoblast to buy stem cell business from Osiris
11 October, 2013 by Dylan Bushell-EmblingMesoblast (ASX:MSB) will pay up to US$100m to acquire the mesenchymal precursor cell business of US-based Osiris Therapeutics.
CSL to pay US$64m to settle class action suit
10 October, 2013 by Dylan Bushell-EmblingCSL (ASX:CSL) has negotiated a proposed settlement to a US class action antitrust lawsuit centred around the company's control of supply of plasma-derived protein therapeutics.
